In a new study, scientists at Duke University School of Medicine have identified a potential new front in the battle against fungal infections, a growing health threat. By determining two structures of a crucial enzyme involved in fungal survival, scientists have pinpointed a pathway that could be key to developing new antifungal drugs.

Health experts at Duke University School of Medicine are scrutinizing the myriad ways in which shifting environmental conditions, from sweltering temperatures to severe storms, shape our well-being.  In university laboratories, North Carolina homes and on the coastlines of faraway places, they've learned not everyone is equally at risk. Their efforts involve pinpointing solutions to help those susceptible to environmental disruptions, which could affect respiratory and cardiovascular health, food security, infection resilience, and mental health.

Nancy Andrews, MD, PhD, is Executive Vice President and Chief Scientific Officer at Boston Children's Hospital and Professor in Residence in Pediatrics at Harvard Medical School. She was Dean of the School of Medicine and Vice Chancellor for Academic Affairs at Duke University from 2007-2017.

R. Sanders “Sandy” Williams, MD’74, HS’77-’80, is a professor of medicine in the Division of Cardiology at Duke University School of Medicine. He was Dean of the School of Medicine from 2001-2007 and Senior Vice Chancellor of Academic Affairs from 2001-2010. He currently serves in advisory roles on issues including Duke Science and Technology and research translation and commercialization.

Mary E. Klotman, BS’76, MD’80, HS’80-85, is Executive Vice President for Health Affairs at Duke University, Dean of Duke University School of Medicine, and Chief Academic Officer for Duke University Health System. She was appointed dean in 2017, after serving for seven years as chair of the Department of Medicine, and re-appointed in 2022.

Three individuals within the School of Medicine and one Duke Health team were among the recipients of the prestigious 2024-25 Duke Presidential Awards.   

Last year, Duke became the first institution in North Carolina to offer lecanemab, the first drug targeting the underlying processes of Alzheimer’s disease that has shown a clinical benefit. Duke now conducts the largest lecanemab clinic in the state, giving early-stage Alzheimer’s patients the gift of time and raising awareness about the need for more research.

Duke researchers found that, in animal models, supporting pre-term fetuses in an artificial womb until they reach late pre-term gestational age results in brain tissue gene expression that more closely resembles that of late pre-term fetuses than those born prematurely.

Duke has a long and influential institutional history of providing electroconvulsive therapy clinical services, training clinicians to thoughtfully and effectively administer ECT, and advancing the science of ECT through cutting-edge research.

Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells along an evolutionary pathway to become broadly neutralizing antibodies. Further tests in primates and humans are planned.